Arrossi Silvina, Temin Sarah, Garland Suzanne, Eckert Linda O'Neal, Bhatla Neerja, Castellsagué Xavier, Alkaff Sharifa Ezat, Felder Tamika, Hammouda Doudja, Konno Ryo, Lopes Gilberto, Mugisha Emmanuel, Murillo Rául, Scarinci Isabel C, Stanley Margaret, Tsu Vivien, Wheeler Cosette M, Adewole Isaac Folorunso, de Sanjosé Silvia
, Instituto Nacional del Cancer, Buenos Aires, Argentina; , American Society of Clinical Oncology, Alexandria, VA; , University of Melbourne, Melbourne, Victoria, Australia; , University of Washington; , PATH, Seattle, WA; , All India Institute of Medical Sciences, New Delhi, India; and , Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; , Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; , Cervivor, Upper Marlboro, MD; , Institut National de Santé Publique, Algiers, Algeria; , Jichi Medical University, Saitama Medical Center, Saitama, Japan; , Sylvester Comprehensive Cancer Center, Miami, FL; , PATH, Kampala, Uganda; , International Agency for Research on Cancer, Lyon, France; , University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; , University of Cambridge, Cambridge, United Kingdom; , University of New Mexico, Albuquerque, NM; and , Ministry of Health, Abuja, Nigeria.
J Glob Oncol. 2017 Mar 17;3(5):611-634. doi: 10.1200/JGO.2016.008151. eCollection 2017 Oct.
To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally.
The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings.
Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ≥ 75%.
In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ≥ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ≥ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus-related cancers and diseases. Basic settings: vaccinating boys is not recommended.
It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
提供全球范围内基于资源分层(四个层级)的宫颈癌一级预防循证建议。
美国临床肿瘤学会召集了一个多学科、跨国的专家小组,成员包括肿瘤学、妇产科、公共卫生、癌症控制、流行病学/生物统计学、卫生经济学、行为/实施科学以及患者权益倡导等领域的专家。专家小组审查了现有指南,并进行了改良的ADAPTE流程以及与其他专家(共识评级小组)的基于共识的正式流程,进行一轮正式评级。
确定并审查了来自五个指南制定者的现有指南集;改编后的建议构成了证据基础。五项系统评价以及成本效益分析为正式的共识流程提供了证据依据,该流程达成了≥75%的共识。
在所有资源环境下,建议9至14岁女孩接种两剂人乳头瘤病毒疫苗,间隔至少6个月,可能长达12至15个月。艾滋病毒呈阳性的个体应接种三剂。资源丰富和强化环境:如果女孩年龄≥15岁且在15岁之前接种了第一剂,她们可以完成全程接种;如果在15岁之前未接种任何剂量,则应接种三剂;在这两种情况下,接种年龄可至26岁。资源有限和基础环境:如果在为9至14岁女孩接种疫苗后仍有足够资源,已接种一剂的女孩可在15至26岁之间接种额外剂量。资源丰富、强化和有限环境:如果优先女性目标人群的覆盖率≥50%、资源充足且具有成本效益,可对男孩进行接种以预防其他非宫颈癌的人乳头瘤病毒相关癌症和疾病。基础环境:不建议为男孩接种。
美国临床肿瘤学会认为,医疗保健提供者和医疗保健系统决策者应以针对可用最高资源层级的建议为指导。本指南旨在补充而非取代当地指南。